NYU College of Dentistry

Long-lasting glaucoma fix? They can see it from here

By GREGORY ZELLER // A Stony Brook biotech looking to carve a nanotech niche in the science of glaucoma treatment is eyeing some impressive laboratory results. Sustained Nano Systems, working closely with Stony Brook University’s Center for Biotechnology, has “achieved positive in-vitro results on long-term sustained delivery of Latanaprost for glaucoma treatment,” according to a company statement. Decoded: The biotech can keep the No. 1 glaucoma drug ticking for 159 days in in-vitro tests, which…